These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21692140)

  • 21. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential interactions between pharmaceuticals and natural health products in Canada.
    Singh SR; Levine MA
    J Clin Pharmacol; 2007 Feb; 47(2):249-58. PubMed ID: 17244776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reporting natural health product related adverse drug reactions: is it the pharmacist's responsibility?
    Walji R; Boon H; Barnes J; Welsh S; Austin Z; Baker GR
    Int J Pharm Pract; 2011 Dec; 19(6):383-91. PubMed ID: 22060233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An innovative model for regulating supplement products: natural health products in Canada.
    Nestmann ER; Harwood M; Martyres S
    Toxicology; 2006 Apr; 221(1):50-8. PubMed ID: 16472903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural Health Products and Diabetes: A Practical Review.
    Necyk C; Zubach-Cassano L
    Can J Diabetes; 2017 Dec; 41(6):642-647. PubMed ID: 28826695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canada's contribution to global research in cardiovascular diseases.
    Nguyen HV; de Oliveira C; Wijeysundera HC; Wong WW; Woo G; Grootendorst P; Liu PP; Krahn MD
    Can J Cardiol; 2013 Jun; 29(6):742-6. PubMed ID: 23219608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk management measures for chemicals in consumer products: documentation, assessment, and communication across the supply chain.
    Bruinen de Bruin Y; Hakkinen PB; Lahaniatis M; Papameletiou D; Del Pozo C; Reina V; Van Engelen J; Heinemeyer G; Viso AC; Rodriguez C; Jantunen M
    J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S55-66. PubMed ID: 17609687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment.
    Jordan SA; Cunningham DG; Marles RJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):198-216. PubMed ID: 20018204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Herbal product use by older adults.
    González-Stuart A
    Maturitas; 2011 Jan; 68(1):52-5. PubMed ID: 20970932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of natural product use between primary care and nephrology patients.
    Grabe DW; Garrison GD
    Ann Pharmacother; 2004; 38(7-8):1169-72. PubMed ID: 15187203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural health product labels: is more information always better?
    Boon HS; Kachan N
    Patient Educ Couns; 2007 Oct; 68(2):193-9. PubMed ID: 17693048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herbal products sparked symptoms.
    Smits M
    Can Nurse; 2001 Jun; 97(6):5. PubMed ID: 11868220
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of natural health products in treating osteoporosis: what is the quality of internet patient advice?
    Whelan AM; Jurgens TM; Bowles SK; Doyle H
    Ann Pharmacother; 2009 May; 43(5):899-907. PubMed ID: 19417114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Industry challenge to best practice risk communication.
    McEntire J; Boateng A
    J Food Sci; 2012 Apr; 77(4):R111-7. PubMed ID: 22429296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assuring the affordability of Canada's health care system.
    Rowand RS; Scully HE
    Clin Invest Med; 1994 Aug; 17(4):328-33. PubMed ID: 7982296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of transfusion related risks: is risk communication to non-experts at all possible?
    Hossenlopp C
    Dev Biol (Basel); 2007; 127():249-58. PubMed ID: 17486898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herbal remedies in the United States: potential adverse interactions with anticancer agents.
    Sparreboom A; Cox MC; Acharya MR; Figg WD
    J Clin Oncol; 2004 Jun; 22(12):2489-503. PubMed ID: 15197212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing the risks of therapeutic products: proceedings of a workshop.
    Kramer JM
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):619-28. PubMed ID: 15641121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Criteria used by Health Canada's Product Safety bureau to determine whether or not regulations are needed to address the hazards associated with a given consumer product.
    Fortin Y
    Inj Prev; 1998 Dec; 4(4):259-60. PubMed ID: 9887413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.